Authorship · Reference

Authorship in medical research

Medical research authorship is governed by the ICMJE criteria — the dominant international standard across clinical and biomedical publishing. The field has also faced distinctive challenges from pharmaceutical industry ghostwriting, large multi-site trials, and CME-linked authorship, which have shaped increasingly rigorous disclosure and contribution requirements.

The step most authors miss

Doing CRediT right? Don’t stop at the statement.

A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.

Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.

The ICMJE as the gold standard in medicine

The International Committee of Medical Journal Editors (ICMJE) sets the dominant authorship standard in medicine through its four criteria: substantial contribution to conception, design, data or analysis; drafting or critical revision; final approval; and accountability. The ICMJE is an ICMJE member-journal group whose Recommendations are followed by thousands of journals, making the criteria effectively universal in clinical and biomedical publishing.

In practice, adherence means that providing only funding, only patient referrals, only statistical support, or only general departmental oversight does not qualify a person for authorship. These contributions belong in acknowledgements or CRediT contributor-roles statements. The standard was strengthened specifically in response to documented abuses in medical authorship.

Pharmaceutical industry ghostwriting

The most widely publicised medical authorship scandals involved pharmaceutical companies paying medical communications agencies to draft manuscripts, then recruiting academic physicians to lend their names to the papers as listed authors. Documents disclosed in litigation over Vioxx (rofecoxib, Merck) and various SSRI drugs showed systematic ghostwriting and ghost-management of publications. The listed academic authors often had limited involvement in study design or manuscript preparation. The consequences included retracted papers, regulatory scrutiny, and much stronger ICMJE and journal requirements for disclosure of writing assistance and industry involvement.

CME and large multi-site trials

Continuing medical education (CME) materials have been another site of authorship concern: industry-funded CME events and supplements have at times featured ghostwritten educational content attributed to clinician speakers. ICMJE and COPE guidance applies equally to CME contexts, though enforcement is more difficult.

Large multi-site clinical trials present a different challenge: with hundreds of investigators across many sites, listing all individual authors becomes impractical. The solution is group authorship, where the trial group is named as the author and a defined subgroup of individuals — those who meet authorship criteria — is identified as taking accountability. CONSORT reporting standards for randomised controlled trials address authorship transparency requirements for trial publications.

BMJ, NEJM and specific journal policies

Leading medical journals enforce their own policies on top of ICMJE. The BMJ requires detailed author contribution statements and explicitly asks authors to state whether a professional medical writer was involved and whether they are disclosed. NEJM requires that all authors vouch for the data and the analysis and that the corresponding author has had access to all study data. Both journals have policies on industry-funded research that require independent analysis and access to data, specifically to prevent the selective reporting documented in past scandals.

Key facts

At a glance

Standard: ICMJE four criteria are the gold standard across biomedical and clinical publishing
Ghostwriting: pharmaceutical industry manuscripts ghostwritten by agencies; led to major reforms
Examples: Vioxx and SSRI litigation disclosed systematic academic-industry ghost-authorship
CME: continuing medical education materials also subject to authorship integrity requirements
Large trials: group authorship plus identified accountable individuals; CONSORT transparency standards
BMJ/NEJM: require author contribution statements and disclosure of professional medical writers
Remedy: CRediT Writing role attribution and mandatory writing-assistance disclosure

Common questions

FAQ

What authorship standard applies to medical research?+

The ICMJE four criteria are the dominant standard across biomedical and clinical publishing: substantial contribution, critical revision, final approval, and accountability. Thousands of journals require or recommend compliance.

What is medical ghostwriting?+

Medical ghostwriting is the practice of having manuscripts — usually for industry-funded research — written by professional medical writers employed by a pharmaceutical company or agency, while academic physicians are listed as the authors. It is condemned by ICMJE and COPE.

How should large clinical trials handle authorship?+

Through group (corporate) authorship: the trial collaboration is listed as the author, with a defined subgroup of individuals who meet ICMJE criteria identified as accountable. CONSORT standards address reporting requirements for trial authorship.

Do BMJ and NEJM have specific authorship rules?+

Yes. Both require detailed author contribution statements, disclosure of professional medical writers, and confirmation that all authors had appropriate access to study data. BMJ explicitly asks about writing assistance; NEJM requires authors to vouch for the data and analysis.

Going deeper